title: Establishment and characterization of a cell-line originated from human mucinous cystadenocarcinoma of the ovary.
abstract: We recently established a cell line (designated 371M) derived from an ovarian mucinous cystadenocarcinoma. The tumor cells were obtained from the ascitic fluid of a 54-year-old Japanese woman while she was undergoing surgery. Adjuvant chemotherapy (combined paclitaxel and carboplatin) was administered, but was ineffective, and she died about 4 months after surgery. The 371M cells continuously propagated in vitro over a period of about 50 months and, to date, have undergone over 100 passages. They proliferated in a monolayered sheet with doubling times of 84 h and 37 h in the 10th and 34th passages, respectively. When transplanted into nude mice, the tumor histopathologically resembled the structure of the original tumor. The 371M cells secreted high levels of CA125 and CA19-9 into the culture medium. There were several abnormal chromosomes in all karyotypes selected at random. Sensitivity of 371M cells to a variety of anti-cancer drugs was examined by in vitro MTT assay, and the results suggested that CPT-11 and CDDP were more effective against 371M cells than other anti-cancer agents.
authors.affiliation: Department of Obstetrics and Gynecology, St. Marianna University School of Medicine, Kawasaki, Japan. sampu@marianna-u.ac.jp
authors.forename: Sojiro
authors.initials: S
authors.lastname: Sato
authors.forename: Yoichi
authors.initials: Y
authors.lastname: Kobayashi
authors.forename: Yoshiaki
authors.initials: Y
authors.lastname: Okuma
authors.forename: Haruhiro
authors.initials: H
authors.lastname: Kondo
authors.forename: Yosuke
authors.initials: Y
authors.lastname: Kanishi
authors.forename: Kaoru
authors.initials: K
authors.lastname: Saito
authors.forename: Kazusige
authors.initials: K
authors.lastname: Kiguchi
mesh_terms: D000818:Animals; D015295:Antigens, Tumor-Associated, Carbohydrate; D000970:Antineoplastic Agents / Q000494:pharmacology; D014408:Biomarkers, Tumor; D002166:Camptothecin / Q000031:analogs & derivatives* / Q000494:pharmacology; D018929:Cell Culture Techniques / Q000379:methods*; D002455:Cell Division; D002945:Cisplatin / Q000494:pharmacology; D018282:Cystadenocarcinoma, Mucinous / Q000235:genetics / Q000473:pathology; D004354:Drug Screening Assays, Antitumor; D005260:Female; D006801:Humans; D000077146:Irinotecan; D007621:Karyotyping; D051379:Mice; D008819:Mice, Nude; D008875:Middle Aged; D009368:Neoplasm Transplantation; D010051:Ovarian Neoplasms / Q000235:genetics / Q000473:pathology; D014407:Tumor Cells, Cultured
chemical_list: D015295:Antigens, Tumor-Associated, Carbohydrate; D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D000077146:Irinotecan; D002945:Cisplatin; D002166:Camptothecin